Research Papers:

Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions

Fu-chao Chen _, Lin-hai Wang, Xiao-yu Zheng, Xiu-min Zhang, Jun Zhang and Lin-Jun Li

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:19236-19243. https://doi.org/10.18632/oncotarget.13705

Metrics: PDF 1745 views  |   HTML 2989 views  |   ?  


Fu-chao Chen1, Lin-hai Wang2, Xiao-yu Zheng3, Xiu-min Zhang1, Jun Zhang4, Lin-Jun Li4

1Department of Pharmacy, Dongfeng Hospital, Hubei University of Medicine, Shiyan, Hubei, 442008, P.R. China

2Department of Pharmacy, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, P.R. China

3International School of Software, Wuhan University, Wuhan, Hubei, 430079, P.R. China

4Department of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, P.R. China

Correspondence to:

Lin-Jun Li, email: [email protected]

Keywords: paclitaxel, dexamethasone, allergic reaction, meta-analysis

Received: September 14, 2016    Accepted: November 19, 2016    Published: November 29, 2016


Background: Dexamethasone premedication is required to prevent paclitaxel-related hypersensitivity reactions (HSRs). Oral dexamethasone (PO-D) has been considered the standard premedication regimen. However, whether intravenous dexamethasone (IV-D) is feasible for preventing paclitaxel-related HSRs is still unclear. We conducted a meta-analysis to compare these two regimens.

Methods: We performed a systematic search in the PubMed, China National Knowledge Infrastructure, and Web of Science databases for relevant articles published before June 2016. Outcomes included HSRs and severe HSRs. Statistical analyses were performed using RevMan 5.2 software.

Result: Six studies comprising 1347 patients were included in the meta-analysis. The PO-D premedication regimen showed a significantly decreased incidence of severe HSRs compared with the IV-D regimen with an OR of 0.53 (95% CI 0.28-0.99, p = 0.05). However, there was no difference in the overall paclitaxel-related HSR rates between the two premedication regimens (OR 0.76, 95% CI 0.55-1.06, p = 0.11). Subgroup analyses according to study type and country of origin showed similar statistical results between the two premedication regimens.

Conclusion: Our meta-analysis showed that the PO-D premedication regimen is superior to the IV-D regimen in preventing paclitaxel-related HSRs. Additional randomized controlled trials are needed to confirm our findings.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13705